The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

εPKC Antagonists for Pain Treatment


Stanford Reference:

04-187


Abstract


Dr. Daria Mochly-Rosen has generated εPKC antagonists that may be used to treat pain. These isozyme-specific antagonists were generated through a new method developed by the inventor. This method changes the biological activity of an isozyme-specific PKC agonist to an antagonist. As an example of the method, a εPKC-specific translocation agonist was converted to an antagonist. This peptide selectively inhibits interaction of εPKC with its anchoring RACK and thus disrupts the function of εPKC. This peptide may be used to treat pain.



Applications


  • Pain treatment
  • Method can be used to:
    • Create isozyme-specific PKC antagonists
    • Create selective inhibitors of other signaling enzymes that undergo inducible protein-protein interactions

Advantages


  • Isozyme-specific PKC antagonist- reduce side effects

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 8/26/2013
 

Licensing Contact


Sara Nakashima, Licensing Associate
650 725 9115 (Direct)
Login to Request Information

[-] Map/Timeline

93-168 Peptides That Modulate Interaction Between PKC and RACK
96-086 Novel method to Deliver Biopolymers into Cells
96-103 εPKC Agonists to Provide Cardioprotection

more technologies

Related Keywords


epsilon protein kinase C   signaling enzymes   pain management   pain   antagonist   nociception   peptide antagonist   PKC   protein kinase c   protein kinase inhibitors   therapeutic peptide   therapeutic: peptides   
 

   

  

Also of Interest...
93-168 Peptides That Modulate Interaction Between PKC and RACK
96-086 Novel method to Deliver Biopolymers into Cells
96-103 εPKC Agonists to Provide Cardioprotection

Recently Viewed...
S04-187 εPKC Antagonists for Pain Treatment